Safe harbors (and other strategies) for life sciences and healthcare ...

5 pages - 683.5 KB
Pressly permissible under the local law of the host country ... safe harbor, life sciences, and healthcare companies routinely.
Document in text mode:
1As published by the American Bar Association in the December 2021 issue of The Health LawyerINTRODUCTIONFor life sciences and healthcare companies ac-customed to operating within the bounds of U.S. fraud and abuse laws, certain gaps be-tween domestic and international anti-cor-ruption laws can cause compliance challenges is article focuses on two such gaps.First, unlike the Anti-Kickback Statute (AKS), the Foreign Corrupt Practices Act (FCPA) lacks safe harbors that expressly permit a range of routine interactions between pharmaceuti-cal, medical device, and healthcare companies, on the one hand, and individual healthcare professionals (HCPs) and institutions, on the other Attorneys from the FCPA Units of the U.S Department of Justice (DOJ) and U.S Securities and Exchange Commission (SEC) generally do not approach these issues from a U.S healthcare compliance perspective; they are often skeptical of certain arrangements with HCPs that are common in the United States and can be struc...
Relevant files:
Health care sharing ministries: what are the risks to consumers and ...
Understanding the final rules to revise the anti-kickback statute ...
Promoting medical products globally - baker mckenzie
Marketing healthcare services-traps for the ...
Expanded availability of anti-kickback statute safe harbors
Discounts as kickbacks for medical equipment